|
|
Vaccine Detail
|
Verpasep Caltespen Vaccine |
| Vaccine Information |
- Vaccine Name: Verpasep Caltespen Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007066
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- HSPD1
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- E7
gene engineering:
- Preparation: This is a vaccine consisting of a fusion of the human papillomavirus (HPV) 16 E7 protein and the Mycobacterium bovis heat shock protein 65 (SGN-00101) (Palefsky et al., 2006).
- Description: This is for Cervical Cancer (NCT00493545). A recombinant chimeric protein composed of the heat shock protein 65 (Hsp65) from Mycobacterium bovis, and the human papilloma viral (HPV) protein E7. Hsp65, similar to other members of its family of proteins, elicits a strong immune response and may be used to design vaccines against a number of different cancers. E7 protein is involved in carcinogenesis of anal and cervical tumors, and represents a tumor antigen that may be specifically targeted by lymphocytes (NCI04) (Palefsky et al., 2006; NCIT_C2811).
|
| Host Response |
|
|
| References |
NCIT_C2811: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2811]
NCT00493545: [https://clinicaltrials.gov/show/NCT00493545/]
Palefsky et al., 2006: Palefsky JM, Berry JM, Jay N, Krogstad M, Da Costa M, Darragh TM, Lee JY. A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. AIDS (London, England). 2006; 20(8); 1151-1155. [PubMed: 16691066].
|
|
